Amarin Corp ADR (AMRN) Stock Price, Quote & News

Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 353 0 166 99020

Website: www.amarincorp.com

Address:

One Central Plaza, 8th Floor 36 Dame Street, Dublin, Ireland

steven1x Sep. 19 at 11:59 PM

$AMRN https://stocktwits.com/steven1x/message/664652735

0 · Reply

CaptBeer Sep. 19 at 11:07 PM

Hello my $AMRN Friends. The English Prescribing data is in. Here’s a summary along with charts: VAZKEPA’s UK prescribing trajectory is becoming hard to ignore. Exact monthly data show VAZKEPA/IPE capsules rising from 1.12M in 2023 to 2.89M in 2024 (+158%), 4.81M in 2025 (+66%), and 3.87M in just Jan–Jul 2026 (+52% vs Jan–Jul 2025). July 2026 hit a record 659,319 capsules. Meanwhile, OMG-3 EE fell from 5.13M capsules in 2023 to 4.97M in 2024, 4.57M in 2025, and 2.60M in Jan–Jul 2026. VAZKEPA’s share of the combined market rose from ~14% in 2023 to ~33% in 2024, ~49% in 2025 and ~60% in Jan–Jul 2026; July reached 62.5%. The key: VAZKEPA is growing while the competing EE market is flat/down. This is both category expansion and share capture. Here’s a link to the slides: https://drive.google.com/file/d/1LEsEjGW1fHbJmUXKG57POCcVsn74eCJA/view?usp=sharing

1 · Reply

Md80dog Sep. 19 at 10:32 PM

$AMRN

0 · Reply

Merlintrader Sep. 19 at 6:41 PM

Amarin ($AMRN) Stock Hub Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/amarin-amrn-stock-hub/

0 · Reply

CaptBeer Sep. 18 at 10:28 PM

BEER GOOD $AMRN GOOD

1 · Reply

buygreensellredchop Sep. 18 at 8:39 PM

$AMRN Does our future rely depend on thus LR patent approval? What are our options is its not approved? 7 years of current patent must be worth atleast 1 billion?

2 · Reply

CaptBeer Sep. 18 at 7:20 PM

$AMRN https://lnkd.in/p/gvJH4hgV

0 · Reply

CaptBeer Sep. 18 at 4:00 PM

$AMRN The company itself is in considerably better financial shape than AMRN’s stock price suggests. Q2 showed: * $314.6M cash * debt-free * $7M positive operating cash flow * third consecutive quarter of positive cash flow * $70M annualized cost reductions * international in-market demand up 59% YoY * Europe up 69% * China up 90% YTD * U.S. IPE market share up to 48% * branded VASCEPA prescriptions up 14% And management continued to expect positive cash flow for full-year 2026. That’s a very different financial profile from the “one-product company burning cash toward extinction” narrative.

3 · Reply

Patrick2343 Sep. 18 at 3:53 PM

$AMRN method patents run out by June 2033, why would anyone buy a company with patents that run out in 7 years when they only have one drug? Jron and his hot air is simply that just hot air. There is no denner master plan he got in way over his head and now he does not know what to do Denner clearly make a poor call on this one

1 · Reply

Patrick2343 Sep. 18 at 3:37 PM

$AMRN If even Jron admits things are not good you know they are really bad the new formulation he promised must not be happening now.

0 · Reply

Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026

Aug 28, 2026, 8:15 AM EDT - 22 days ago

New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients

Aug 24, 2026, 8:15 AM EDT - 26 days ago

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026

2026-08-21T10:35:41.000Z - 4 weeks ago

Amarin reinstated with an Underweight at JPMorgan

Aug 4, 2026, 11:41 PM EDT - 6 weeks ago

Amarin Corporation Transcript: Transcript

Jul 30, 2026, 4:08 AM EDT - 7 weeks ago

Amarin Corporation Slides

Jul 29, 2026, 4:31 PM EDT - 7 weeks ago

Amarin Corporation Quarterly report

Jul 29, 2026, 7:19 AM EDT - 7 weeks ago

Amarin Corporation Earnings release

Jul 29, 2026, 7:00 AM EDT - 7 weeks ago

Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence

Jul 15, 2026, 8:00 AM EDT - 2 months ago

Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026

Jul 8, 2026, 3:21 PM EDT - 2 months ago

Amarin Corporation Transcript: Transcript

Jul 8, 2026, 12:06 PM EDT - 2 months ago

Amarin Corporation Transcript: Transcript

Jun 30, 2026, 4:15 PM EDT - 2 months ago

Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape

May 27, 2026, 8:00 AM EDT - 3 months ago

New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia

Apr 29, 2026, 10:05 AM EDT - 4 months ago

Amarin Corporation Transcript: Transcript

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Amarin Corporation Slides: Corporate presentation

Apr 29, 2026, 7:00 AM EDT - 4 months ago

Amarin Reports 2026 First Quarter Financial Results

Apr 15, 2026, 8:00 AM EDT - 5 months ago

Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026

2026-03-18T12:41:54.000Z - 6 months ago

Amarin highlights new recommendation for treatment of CV risk

2026-03-16T12:27:24.000Z - 6 months ago

Amarin to present data in patients at extreme cardiovascular risk

2026-03-02T13:26:30.000Z - 6 months ago

Amarin highlights recent data published on REDUCE-IT study

2026-02-25T12:14:50.000Z - 6 months ago

Amarin CFO says ‘well positioned’ to deliver on 2026 strategic priorities

2026-02-23T13:23:34.000Z - 6 months ago

Amarin issues call to action for American Heart Month

Feb 23, 2026, 8:00 AM EST - 6 months ago

This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease

Jan 16, 2026, 2:44 PM EST - 8 months ago

US Supreme Court to hear 'skinny label' patent fight involving Amarin

2026-01-09T12:13:43.000Z - 8 months ago

Amarin comments on recent innovations for patients with elevated triglycerides

Jan 9, 2026, 7:00 AM EST - 8 months ago

Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization

2026-01-08T12:06:26.000Z - 8 months ago

Amarin expects Q4 net revenue $48M-$43M

2025-11-10T00:10:10.000Z - 10 months ago

Amarin announces new post hoc analysis of aspirin use in REDUCE-IT

Nov 9, 2025, 4:15 PM EST - 10 months ago

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

Nov 3, 2025, 8:30 AM EST - 10 months ago

Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025

2025-10-29T11:11:18.000Z - 10 months ago

Amarin reports Q3 EPS (2c) vs (6c) last year

2025-10-27T12:05:31.000Z - 10 months ago

Amarin issues statement related to recent action by FDA for fenofibrate drugs

2025-10-14T12:10:55.000Z - 11 months ago

Amarin, HLS Therapeutics present REDUCE-IT, EPA mechanistic data

Oct 14, 2025, 8:00 AM EDT - 11 months ago

Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress

2025-09-01T12:30:11.000Z - 1 year ago

Amarin presents new REDUCE-IT analyses

Aug 31, 2025, 8:30 AM EDT - 1 year ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

Aug 30, 2025, 8:30 AM EDT - 1 year ago

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

2025-08-25T12:05:06.000Z - 1 year ago

Amarin announces upcoming presentations at ESC Congress 2025

Aug 25, 2025, 8:00 AM EDT - 1 year ago

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025

2025-07-30T11:11:52.000Z - 1 year ago

Amarin expects accelerated in-market demand in Europe

Jul 30, 2025, 7:00 AM EDT - 1 year ago

Amarin Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 7:30 AM EDT - 1 year ago

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

2025-06-24T11:05:33.000Z - 1 year ago

Amarin announces exclusive license, supply agreement with Recordati

Jun 24, 2025, 7:05 AM EDT - 1 year ago

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE

Apr 29, 2025, 4:15 PM EDT - 1 year ago

Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 28, 2025, 4:15 PM EDT - 1 year ago

Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Apr 9, 2025, 7:30 AM EDT - 1 year ago

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Apr 7, 2025, 7:30 AM EDT - 1 year ago

Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors

Mar 19, 2025, 12:45 PM EDT - 1 year ago

Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance

Mar 19, 2025, 7:30 AM EDT - 1 year ago

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Feb 27, 2025, 9:00 AM EST - 1 year ago

Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering

Feb 19, 2025, 8:30 AM EST - 1 year ago

Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025

Dec 16, 2024, 7:00 AM EST - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® in Italy

Dec 13, 2024, 9:00 AM EST - 1 year ago

Amarin Appoints Peter Fishman Chief Financial Officer

Sep 9, 2024, 7:30 AM EDT - 2 years ago

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting

Aug 22, 2024, 8:30 AM EDT - 2 years ago

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

Jul 31, 2024, 7:00 AM EDT - 2 years ago

Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 17, 2024, 4:15 PM EDT - 2 years ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

Jul 17, 2024, 8:00 AM EDT - 2 years ago

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

Jul 8, 2024, 7:30 AM EDT - 2 years ago

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

Jun 7, 2024, 7:16 PM EDT - 2 years ago

LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok

Jun 4, 2024, 7:30 AM EDT - 2 years ago

Amarin Board of Directors Announces CEO Transition

May 28, 2024, 8:15 AM EDT - 2 years ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

May 6, 2024, 8:00 AM EDT - 2 years ago

Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 1, 2024, 7:00 AM EDT - 2 years ago

Amarin Reports First Quarter 2024 Business Update and Financial Results

Apr 24, 2024, 2:00 PM EDT - 2 years ago

Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

Apr 22, 2024, 8:00 AM EDT - 2 years ago

Amarin Announces Results of Annual General Meeting of Shareholders

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

Apr 8, 2024, 8:00 AM EDT - 2 years ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

Apr 6, 2024, 3:30 PM EDT - 2 years ago

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Apr 3, 2024, 8:00 AM EDT - 2 years ago

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Feb 29, 2024, 7:00 AM EST - 2 years ago

Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

steven1x Sep. 19 at 11:59 PM

$AMRN https://stocktwits.com/steven1x/message/664652735

0 · Reply

CaptBeer Sep. 19 at 11:07 PM

1 · Reply

Md80dog Sep. 19 at 10:32 PM

$AMRN

0 · Reply

Merlintrader Sep. 19 at 6:41 PM

Amarin ($AMRN) Stock Hub Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/amarin-amrn-stock-hub/

0 · Reply

CaptBeer Sep. 18 at 10:28 PM

BEER GOOD $AMRN GOOD

1 · Reply

buygreensellredchop Sep. 18 at 8:39 PM

$AMRN Does our future rely depend on thus LR patent approval? What are our options is its not approved? 7 years of current patent must be worth atleast 1 billion?

2 · Reply

CaptBeer Sep. 18 at 7:20 PM

$AMRN https://lnkd.in/p/gvJH4hgV

0 · Reply

CaptBeer Sep. 18 at 4:00 PM

3 · Reply

Patrick2343 Sep. 18 at 3:53 PM

1 · Reply

Patrick2343 Sep. 18 at 3:37 PM

$AMRN If even Jron admits things are not good you know they are really bad the new formulation he promised must not be happening now.

0 · Reply

Patrick2343 Sep. 18 at 3:36 PM

$AMRN JRoon71 Nobody cares about the 300 million is cash they have one drug even the worlds biggest pumper Jron finally realized the company is dead right now its why you need more than one drug. The company is in bad shape with few options right now. Denner has done nothing at all to change things. I think this is the key. Without a patent on the new formulation, there will be little interest in the current Vascepa formulation from BP's. Nobody wants to compete with 9 other generics. It's possible it could get sold for scraps, with the hope that they can somehow resurrect something from the new formulation. But otherwise, without the patent, the entire trajectory changes for us.

1 · Reply

BobGood Sep. 18 at 3:24 PM

$AMRN Just a simple question to all longs.. We always see some positive news from different people, for example from Capbeer, evila,, some blocked people with several highlighted underlined in diff colors, glittering messages, etc… on the prospeive or promising future for Vascepa.. My question is if WS knows even a fraction of these promising future news, we should be at least > book value today. But that’s not happening right now.. That means, WS either not aware of these future or not confident on their promising future or not confident on Amarin management to fulfill the promising future… GL

2 · Reply

bennfine Sep. 18 at 2:10 PM

$AMRN who the heck is selling???

0 · Reply

bennfine Sep. 18 at 11:27 AM

$AMRN 53 shares!

0 · Reply

CaptBeer Sep. 17 at 11:56 PM

$AMRN I still Like Novo Nordisk! https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177967528

0 · Reply

DoMoreCharity Sep. 17 at 10:43 PM

$AMRN https://www.linkedin.com/pulse/when-promising-trials-neutral-patients-still-need-us-viet-tzizc?utm_source=share&utm_medium=member_ios&utm_campaign=share_via

0 · Reply

EnVila Sep. 17 at 6:13 PM

$AMRN In Spain, the High Court of Justice has upheld the decision of Osakidetza (the Basque public Healthcare Service) to deny funding for a medication costing roughly 840,000 euros per year. The case involves a patient diagnosed with generalized acquired lipodystrophy, a rare condition that causes progressive fat loss and dangerous metabolic complications. Her endocrinologist requested metreleptina (marketed as Myalepta), an orphan drug not officially marketed or publicly funded in Spain for this use. Experts argued that the drug's clinical efficacy is uncertain and that other funded treatments like VAZKEPA could achieve superior reductions in triglycerides. https://gananzia.com/la-justicia-avala-que-osakidetza-niegue-a-una-paciente-un-tratamiento-de-840-000-euros-anuales-porque-su-eficacia-clinica-es-discutida/

1 · Reply

revivedfossil Sep. 17 at 2:49 PM

$AMRN crazy low volume

2 · Reply

MorrisBorris2Duex Sep. 17 at 11:24 AM

$AMRN Volume: Pre-market 1.246212

0 · Reply

buygreensellredchop Sep. 17 at 3:22 AM

$AMRN Pisses me off they haven't started the share buy backs. Why go through the headache and expense if you weren't going to do it? Shit heads..

0 · Reply

Bozwell19 Sep. 16 at 3:30 PM

$AMRN Why is Amrn worth less today than 13 years ago?? .70 cents vs $1.29 . Just don't understand this.

3 · Reply

Finitemaf Sep. 16 at 8:57 AM

$AMRN yawn

0 · Reply

Market Cap	287.91M
Revenue (ttm)	213.65M
Net Income (ttm)	-38.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-18.16%
Debt to Equity Ratio	0.00

Volume	50,600
Avg Vol	66,636
Day's Range	N/A - N/A
Shares Out	21.12M
Stochastic %K	37%
Beta	0.76
Analysts	Hold
Price Target	$13.33